Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,453,000 | 1,965,000 | 1,275,000 | 534,000 | 725,000 |
| Receivables | 3,027,000 | 2,926,000 | 2,828,000 | 2,815,000 | 2,693,000 |
| Inventories | 3,117,000 | 2,943,000 | 2,921,000 | 2,861,000 | 2,867,000 |
| Other current assets | 729,000 | 661,000 | 701,000 | 613,000 | 756,000 |
| TOTAL | $8,684,000 | $8,794,000 | $8,035,000 | $7,121,000 | $7,335,000 |
| Non-Current Assets | |||||
| PPE Net | 4,063,000 | 4,036,000 | 3,795,000 | 3,461,000 | 3,389,000 |
| Intangibles | 25,596,000 | 25,301,000 | 25,376,000 | 25,336,000 | 23,906,000 |
| Other Non-Current Assets | 6,007,000 | 5,541,000 | 5,501,000 | 5,642,000 | 5,510,000 |
| TOTAL | $35,666,000 | $34,878,000 | $34,672,000 | $34,439,000 | $32,805,000 |
| Total Assets | $44,351,000 | $43,673,000 | $42,707,000 | $41,559,000 | $40,140,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 41,000 | 299,000 | 483,000 | 480,000 | 777,000 |
| Accounts payable and accrued liabilities | 1,141,000 | 1,144,000 | 1,002,000 | 962,000 | 1,004,000 |
| Accrued Expenses | 2,514,000 | 3,201,000 | 2,981,000 | 2,797,000 | 2,354,000 |
| Other current liabilities | 875,000 | 795,000 | 862,000 | 952,000 | 923,000 |
| TOTAL | $4,571,000 | $5,439,000 | $5,328,000 | $5,190,000 | $5,058,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 10,988,000 | 11,137,000 | 11,117,000 | 11,107,000 | 10,532,000 |
| Other Non-Current Liabilities | 2,471,000 | 2,407,000 | 2,390,000 | 2,385,000 | 1,948,000 |
| TOTAL | $13,676,000 | $13,762,000 | $13,749,000 | $13,716,000 | $12,636,000 |
| Total Liabilities | $18,247,000 | $19,201,000 | $19,077,000 | $18,906,000 | $17,694,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,486,355 | 1,483,885 | 1,482,442 | 1,481,752 | 1,479,446 |
| Common Shares | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 |
| Retained earnings | 6,912,000 | 5,571,000 | 4,899,000 | 4,144,000 | 3,347,000 |
| Other shareholders' equity | -158,000 | -370,000 | -454,000 | -487,000 | 206,000 |
| TOTAL | $26,104,000 | $24,472,000 | $23,630,000 | $22,653,000 | $22,446,000 |
| Total Liabilities And Equity | $44,351,000 | $43,673,000 | $42,707,000 | $41,559,000 | $40,140,000 |